KRAS and neoplasm: However, as discussed above, tumor cells after KRAS-driven metabolic reprogramming can be blocked in the S or G2/M phase due to glutamine deprivation and therefore can be effectively targeted by transaminase inhibitors or S-phase-specific toxic compounds during the therapy.